LBA19 - Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
| Autor: | Mok, T.S.K., Cheng, Y., Zhou, X., Lee, K.H., Nakagawa, K., Niho, S., Linke, R., Rosell, R., Corral, J., Migliorino, M.R., Pluzanski, A., Noonan, K., Tang, Y., Wilner, K.D., Wu, Y.-L. |
|---|---|
| Zdroj: | In Annals of Oncology November 2019 30 Supplement 9:ix200-ix201 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|